Natco Pharma, along with its marketing partner Arrow International, recently launched the first generic of Revlimid in dosage strengths of 5 mg, 10 mg, 15 mg and 25 mg.
Thirty-five generic manufacturers have signed agreements with the MPP to produce low-cost, generic versions of Pfizer’s oral COVID-19 treatment nirmatrelvir in combination with ritonavir for 95 low- and middle-income countries.
OneEvent Technologies president and CEO Kurt Wedig shares the benefits of his company’s technology in helping to prevent expensive breakdowns, reduce energy costs and improve productivity.